Trial Watch: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Important context
- Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
In plain English
The 30-second version
What happened?
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Why does it matter?
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
What does this not prove?
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Keep reading for evidence stage, limitations, study details, and sources.
What changed: ClinicalTrials.gov lists A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (NCT04658862) as a Phase 3 interventional cancer study. The registry status is Active Not Recruiting, with the record last updated 2026-08-28.
Study snapshot: Phase 3; Active Not Recruiting; planned enrollment 518. Conditions listed: Urinary Bladder Neoplasms. A primary outcome listed by the registry is: Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event.
This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.
Population / Applicability
Studied in: Participants age 18 Years and older with Urinary Bladder Neoplasms who meet the study-specific registry eligibility criteria. (Adults)
Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.
Full evidence details
- Study design
- Not specified in this summary
- Sample size
- 518
- Primary outcome
- Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event
- Replication
- Unknown
Funding & Conflicts
ClinicalTrials.gov lists the lead sponsor as Janssen Research & Development, LLC. Sponsorship is reported for transparency and does not establish efficacy.
Regulatory status by jurisdiction
Country or region not specified
- Status
- Investigational
- Last verified
- 2026-08-28
Cancer-type scope for this record is not yet recorded.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-08-28
Primary evidence supporting this story
- ClinicalTrials.gov — NCT04658862 (opens in a new tab) (Clinical-trial registry) NCT04658862 Primary source NCT04658862
ClinicalTrials.gov — NCT04658862. NCT04658862.
Last reviewed
Trial Watch: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
https://cancerdiscoveries.com/discoveries/trial-watch-a-study-of-tar-200-in-combination-with-cetrelimab-versus-concurrent-chemoradiotherapy-in-participants-with-muscle-invasive-bladder-cancer-mibc-of-the-bladder/
Research type: Registered later-phase trial
What This Means
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
What This Doesn't Mean
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Why It Matters
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
Important Limitations
- Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
Primary sources
- ClinicalTrials.gov — NCT04658862 — https://clinicaltrials.gov/study/NCT04658862 (NCT04658862)
Date verified: 2026-08-28
Correction status: No correction or retraction